Within Major Pharmaceutical Preparations industry 476 other companies have achieved higher Quick Ratio than Bespoke Extracts Inc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 0 to 3984.

Explain Quick Ratio?
How much Cash & cash equivalents BSPK�s has?
What are BSPK�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BSPK Quick Ratio	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3
Y / Y Current Liabilities Change	8.38 %	-5.49 %	-3.08 %	-36.2 %	86.73 %
Y / Y Cash & cash equivalent Change	-	-	-	813.71 %	-
Quick Ratio MRQ	-	-	-	0.06	-
BSPK's Total Ranking	# 3984	# 0	# 0	# 3995	# 0
Seq. Current Liabilities Change	31.3 %	14.87 %	18.78 %	-39.51 %	14.49 %
Seq. Cash & cash equivalent Change	-	-	-	-	-

Quick Ratio third quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 477
Healthcare Sector	# 924
Overall Market	# 3984

Quick Ratio Statistics
High	Average	Low
222.81	19.1	0
(May 31 2014)		(May 31 2020)

Financial Statements
Bespoke Extracts Inc's Current Liabilities	$ 2 Millions	Visit BSPK's Balance sheet
Bespoke Extracts Inc's Cash & cash equivalent	$ 0 Millions	Visit BSPK's Balance sheet
Source of BSPK's Sales		Visit BSPK's Sales by Geography

Cumulative Bespoke Extracts Inc's Quick Ratio

BSPK's Quick Ratio for the trailling 12 Months

BSPK Quick Ratio	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months
Y / Y Current Liabilities TTM Growth	-9.27 %	1.63 %	21.71 %	23.46 %	64.88 %
Y / Y Cash & cash equivalent TTM Growth	186.95 %	186.95 %	186.95 %	1032.14 %	-13.99 %
Quick Ratio TTM	0.01	0.01	0.01	0.01	0
Total Ranking TTM	# 4298	# 3349	# 3335	# 3659	# 3480
Seq. Current Liabilities TTM Growth	2.66 %	-1.5 %	-0.71 %	-9.63 %	14.99 %
Seq. Cash & cash equivalent TTM Growth	0 %	0 %	-19.29 %	255.54 %	0 %

Quick ratio ranking by company, industry and sector >> Back to BSPK Financial Strength Comparisons >> Go to Compare BSPK Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the unchanged in Current Liabilities in the Q3 2025 to $1.87 millions, cumulative Quick Ratio remained unchanged at 0.01 below the Bespoke Extracts Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 511 other companies have achieved higher Quick Ratio than Bespoke Extracts Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 3349 to 4298.

Explain Quick Ratio?
How much Cash & cash equivalents BSPK�s has?
What are BSPK�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 512
Healthcare Sector	# 1037
Within the Market	# 4298

trailing twelve months Quick Ratio Statistics
High	Average	Low
74.89	3.59	0
(Feb 28 2015)		(Sep 30 2024)

Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry

Quick Ratio

Sep 30 2025 MRQ Cash & cash equivalent

Sep 30 2025 MRQ Current Liabilities

Date modified: 2026-08-29T17:14:32+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.